BociMed

About BociMed

Shanghai BociMed Pharmaceutical Co., Ltd. operates as a comprehensive pharmaceutical research, development, and manufacturing service platform. Founded in 2012 and headquartered in Shanghai, China, the company has established itself as a key player in the contract research organization (CRO) and contract development and manufacturing organization (CDMO) sectors. BociMed focuses on providing integrated services for small molecule drugs to pharmaceutical companies globally.

The company's business model revolves around a dual approach: developing its own pipeline of innovative and modified new drugs while also offering extensive CRO/CDMO services. Its client base consists of global pharmaceutical enterprises seeking competitive drug development and manufacturing solutions. Revenue is generated through these integrated services, which cover the entire drug lifecycle from early-stage synthesis and process development to clinical trial support and commercial manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. BociMed has demonstrated significant growth, securing $29.3 million in total funding over three rounds, with its latest Series C funding of $14.6 million completed on February 16, 2023. Investors include firms like Guoxin Investment, Xingfu Capital, and Shanghai STVC Group.

BociMed's core service offerings are extensive. The company has R&D centers in Shanghai and Nanjing, a clinical company in Chengdu, and a manufacturing base capable of producing materials from gram to ton scale. Its expertise spans small molecule manufacturing, Chemistry, Manufacturing, and Controls (CMC) services, and advanced drug delivery technologies, including oral, parenteral, ophthalmic, and transdermal systems. The company's internal drug pipeline focuses on therapeutic areas such as oncology, central nervous system (CNS) disorders, ophthalmology, and respiratory diseases. BociMed possesses a robust intellectual property portfolio with nearly 170 applied patents, 52 of which have been authorized.